The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,126.00
Bid: 12,124.00
Ask: 12,128.00
Change: -30.00 (-0.25%)
Spread: 4.00 (0.033%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Vaccine progress lift stocks, dollar still sickly

Mon, 23rd Nov 2020 09:53

* AstraZeneca vaccine returns stocks to February levels

* Australia eases lockdowns, U.S. vaccines in sight

* 2020 asset performance http://tmsnrt.rs/2yaDPgn

* World FX rates in 2020 http://tmsnrt.rs/2egbfVh

*

By Lawrence White and Andrew Galbraith

LONDON/SHANGHAI, Nov 23 (Reuters) - Shares and oil prices
rose on Monday while the dollar fell as investors pinned hopes
for economic revival on coronavirus vaccines, even as the world
contended with surging case numbers and delays to fresh U.S.
stimulus.

The STOXX index of Europe's 600 largest shares rose
0.5% to its highest since February after AstraZeneca
become the latest major drugmaker to say its vaccine for the
virus could be around 90% effective.

Brent crude futures rose nearly 2% as traders eyed a
recovery in crude demand due to the successful vaccine trials,
while the euro edged up to 1.1864 as the dollar tested
the bottom of a range it has been in for the last few months.

The vaccine developed by AstraZeneca and Oxford University
is the third major trial to report success after U.S.-based
Moderna Inc and Pfizer Inc with Germany's
BioNTech SE , sending pandemic-weary investors
to take on risk in hopes of a swift economic recovery.

Their optimism also comes after a top official of the U.S.
government's vaccine development effort said Sunday that the
first vaccines could be given to U.S. healthcare workers and
others recommended by mid-December.

Despite the backdrop of accelerating COVID-19 infections in
the United States, the forecast helped to raise hopes that
lockdowns that have paralysed the global economy could be
nearing an end.

"Today's vaccine news is positive, but it is only partly
responsible for the rally in stock markets this morning, which
is also being driven by the news that the U.S. hopes to start
the vaccination program in under three weeks," said Philip Shaw,
chief economist at Investec in London.

The rally showed investors are willing to look past the grim
U.S. case numbers -- cases topped 12 million over the weekend --
and weak European economic data released on Monday.

IHS Markit's flash composite Purchasing Managers' Index,
which tracks the manufacturing and services sectors that
together account for more than two-thirds of the German economy,
edged down to 52.0 from 55.0.

The European share rally took the region's November gains to
15% and followed another record high for Asian equities even
before the announcement of latest vaccine news.

MSCI's broadest index of Asia-Pacific shares outside Japan
looked set to end the day 0.8% higher.

Australian shares gained 0.3% as the country eased
some COVID-19 restrictions. Most of the country has seen no new
community infections or deaths in several weeks.

Chinese bluechips had finished 1% higher, Seoul's KOPSI
climbed 1.9% and Bangkok jumped 2.2% to hit a
five-month high.

GOLD LOSING ITS SHINE

Analysts said the gains belied some uncertainty as monetary
and fiscal help for the U.S. economy remained elusive.

U.S. Treasury Secretary Steven Mnuchin said last week that
key pandemic lending programs at the Federal Reserve would
expire on Dec. 31, putting the outgoing Trump administration at
odds with the central bank and potentially adding stress to the
economy.

"Discussion is only beginning and may take some time if the
recent partisan disagreements over the composition and magnitude
of fiscal spending are any indication," analysts at ANZ said in
a note.

U.S. e-mini futures for the S&P 500 were 0.7% higher
at 3,577 in Europe. Wall Street's main markets had dropped 0.4%
to 0.8% on Friday on the combination of aid doubts and the
country's surging coronavirus infection rates.

With the vaccine news and dollar index, which tracks
the dollar against a basket of six major rivals, down to 92.264,
commodity markets were still bullish, with traders optimistic
about a recovery in crude demand pushing oil higher.

Brent crude futures rose 63 cents, or 1.4%, to
$45.59 a barrel in London. West Texas Intermediate crude
gained 49 cents, or 1.2%, to $42.91 a barrel. Both benchmarks
jumped 5% last week.

Safe-haven gold, meanwhile, drifted at $1,872 per
ounce, having lost almost 10% since peaking in earlier August.

"Positive sentiment continues to be driven by the recent
good news about the efficacy of coronavirus vaccines in
development and the expectation that the OPEC+ meeting at the
end of this month could see the group extend current cuts by
three to six 6 months," said Stephen Innes, chief global markets
Strategist at Axi, a financial services firm.

(Reporting by Andrew Galbraith; editing by Richard Pullin,
Larry King)

More News
Today 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
Today 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
Today 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.